Viewing Study NCT01854294

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:33 AM
Ignite Modification Date: 2026-02-20 @ 5:58 PM
Study NCT ID: NCT01854294
Status: COMPLETED
Last Update Posted: 2021-04-27
First Post: 2013-05-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)
Sponsor: Genervon Biopharmaceuticals, LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Amyotrophic Lateral Sclerosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ALS View
None motorneuron disease View
None Central Nervous System (CNS) disease View
None neurodegeneration View
None neuroprotective View
None mechanisms of action View
None pathways View
None biomarkers View
None Cerebral Spinal Fluid (CSF) View
None blood biomarkers View
None multi-factorial View
None multisystem View
None single target View
None pathogenic mechanisms View
None Protein Bands Selection by Function View
None in silico analysis View
None active site View
None protein View
None peptide View
None embryonic stage View
None endogenous View
None master regulators View
None fetal development View
None embryonic development View
None common pathways View
None Blood Brain Barrier (BBB) View
None anti-inflammatory View
None anti-apoptotic View
None anti-oxidative View
None regenerative View
None distress signals View
None neurotrophin View
None Motoneuronotrophic factor (MNTF) View
None ALS model View
None life span View
None disease onset View
None grip strength View
None protein expression View
None DNA microarray View
None differential expression View
None Phase 1 clinical trial View
None rare disease View
None common underlying pathogenic mechanisms View
None neurological deficits View
None gene mutation View
None misfolded proteins View
None inadvertent errors View
None modulation of genes View
None master regulator peptide drug View
None ALS related genes View
None mitochondria dysfunction View
None excitotoxicity View
None axonal transport View
None oxidative stress View
None protein aggregation View
None pathogenesis View
None target biomarkers View
None efficacy biomarkers View